MELISSA CALAHAN: Open Payments
NPI 1750706172 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463 in 23 payments from 12 companies in 2025. Trend: 2023 $492 · 2024 $348 · 2025 $463
Food & beverage: $463
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $116 |
| Biogen, Inc. | 3 | $86 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $60 |
| Dexcom, Inc. | 1 | $35 |
| MILLICENT US INC | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Lilly USA, LLC | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Exeltis, USA Inc. | 1 | $16 |
Products named: Veozah, ZURZUVAE, Dexcom G6 Transmitter, MYFEMBREE, ZEPBOUND, Lynkuet, FEMRING, FEMLYV.
Industry payments across KS — which companies pay providers there.
